Source:http://linkedlifedata.com/resource/pubmed/id/20349137
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
2010-6-25
|
| pubmed:abstractText |
Clinical management of chondrosarcoma remains a challenging problem, largely due to the toxicity and resistance of this tumor to conventional chemotherapy. Programmed Cell Death 5 (PDCD5) is a protein that accelerates apoptosis in different cell types in response to various stimuli, and has been shown to be down-regulated in many cancer tissues. In this study, mRNA and protein levels of PDCD5 were found to be up-regulated in cisplatin-treated SW1353 chondrosarcoma cells compared with untreated cells. Recombinant human PDCD5 (rhPDCD5) was also shown to sensitize chondrosarcoma cells to cisplatin-based chemotherapy, with inhibition of cell growth and apoptosis detected both in vitro and in vivo. Increased expression of Bax and decreased expression of Bcl-2 were also observed, along with release of cytochrome c from mitochondria into the cytosol. Additionally, cleavage of caspase-9 and caspase-3, as well as the cleavage of poly (ADP-ribose) polymerase (PARP), were detected, suggesting that sensitization of chondrosarcoma cells involves the intrinsic mitochondrial apoptosis pathway. In vivo, the treatment of a xenograft model of chondrosarcoma with rhPDCD5 and cisplatin significantly inhibited tumor cell proliferation and induced apoptosis compared to treatment with cisplatin alone. Overall, these data provide a theoretical basis for the administration of rhPDCD5 and cisplatin for the treatment of patients with chondrosarcoma.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Apoptosis Regulatory Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochromes c,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/PDCD5 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/bcl-2-Associated X Protein
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
1573-675X
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
15
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
805-13
|
| pubmed:meshHeading |
pubmed-meshheading:20349137-Animals,
pubmed-meshheading:20349137-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20349137-Apoptosis,
pubmed-meshheading:20349137-Apoptosis Regulatory Proteins,
pubmed-meshheading:20349137-Bone Neoplasms,
pubmed-meshheading:20349137-Cell Line, Tumor,
pubmed-meshheading:20349137-Chondrosarcoma,
pubmed-meshheading:20349137-Cisplatin,
pubmed-meshheading:20349137-Cytochromes c,
pubmed-meshheading:20349137-Female,
pubmed-meshheading:20349137-Humans,
pubmed-meshheading:20349137-Mice,
pubmed-meshheading:20349137-Mice, Inbred BALB C,
pubmed-meshheading:20349137-Mice, Nude,
pubmed-meshheading:20349137-Neoplasm Proteins,
pubmed-meshheading:20349137-Recombinant Proteins,
pubmed-meshheading:20349137-Xenograft Model Antitumor Assays,
pubmed-meshheading:20349137-bcl-2-Associated X Protein
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo.
|
| pubmed:affiliation |
Department of Orthopaedics, Peking University Third Hospital, 49 North Garden Road, Beijing, 100191, China.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|